Developer docs
API playgroundTry for free, no card

Search company profiles

Centenary Institute

Full company profile

uuid002eosg

Namestring
Centenary Institute
Legal namestring
Centenary Institute of Cancer Medicine and Cell Biology
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Centenary Institute (legally Centenary Institute of Cancer Medicine and Cell Biology) is an independent, nonprofit medical research institute headquartered at Royal Prince Alfred Hospital in Camperdown, Sydney, Australia. Established around 1980, the institute operates across five research centres: Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy. Research spans cancer (melanoma, breast, liver, lung, AML), cardiovascular disease, infectious diseases (particularly tuberculosis and COVID-19), rare diseases, liver disease, diabetes, respiratory diseases, and age-related conditions. The institute is formally affiliated with the University of Sydney and Sydney Local Health District, enabling direct clinical translation through co-location with hospital infrastructure and partnerships with organisations such as Chris O'Brien Lifehouse, Garvan Institute, and NSW Health Pathology.

The institute employs advanced biomedical technologies including a PC3 high-containment facility for live pathogen research, spatial biology platforms developed with the University of Sydney, a multiplex mRNA vaccine platform (commercialised via the Vaxosome spin-out), a mammalian cell protein evolution platform combining directed evolution with machine learning, and the Invasion-Block melanoma screening tool. AI and machine learning are applied within dedicated programmes including protein design and computational biomedicine. Revenue is generated through a diversified mix of competitive government grants (NHMRC, MRFF, ARC, NSW Health, Cancer Australia), philanthropic donations under Deductible Gift Recipient status, industry partnerships with pharmaceutical and biotech firms, financial partnerships with charitable foundations such as Snow Medical Research Foundation ($15.5M) and Breakthrough T1D, and commercialisation/licensing income from spin-out companies. The institute does not sell commercial products and operates on a grant-funded, nonprofit model with no publicly disclosed revenue or ARR figures.

Short descriptiontext

Centenary Institute is an independent nonprofit medical research institute in Sydney, Australia, conducting translational research across cancer, cardiovascular, infectious, rare, and age-related diseases through five research centres, affiliated with the University of Sydney and Sydney Local Health District.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCamperdown, Australia
HQ citystring
Camperdown
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical research institute, biomedical research, cancer research, infectious disease research, cardiovascular research
Industry2 codes
PRIMARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYEDAHABAC
Health & Biomedical Research Universities (Academic Medical Center–Affiliated)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Medical Research
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Government Research Grants
TypeSubscription Recurring
Description

Competitive funding from Australian government bodies including NHMRC, MRFF (Medical Research Future Fund), NSW Cardiovascular Research Capacity Program, ARC Discovery Projects, and Cancer Australia. These grants support specific research programs and projects across disease areas.

centenary.org.au
2Donations and Philanthropy
TypeOthers
Description

Charitable donations from individuals, supporters, and trusts including workplace giving programs, fundraising events, bequests, and donations in memory. The institute operates with Deductible Gift Recipient (DGR) status enabling tax-deductible donations.

centenary.org.au
3Commercialisation and Licensing
TypeLicensing Royalties
Description

Revenue from spin-out companies and commercial partnerships arising from research discoveries, such as Vaxosome mRNA vaccine technology. May include licensing royalties from patented discoveries.

centenary.org.au
4Industry Partnerships and Grants
TypeProfessional Services
Description

Funding from pharmaceutical companies, biotech firms, and charitable foundations including Breakthrough T1D, Tour de Cure, Snow Medical Research Foundation ($15.5M), and others for specific research collaborations.

centenary.org.au
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Centenary Institute is an independent medical research institute that conducts laboratory and translational research across five research centres (Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy). It translates basic science discoveries into clinical applications through hospital partnerships, commercialises research via spin-out companies (e.g., Vaxosome), and trains postdoctoral and postgraduate students.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • TB vaccine candidates developed including fully synthetic TB vaccine and CysVac2 protein fusion vaccine with lung-resident memory T cell promotion.
+4 more records
Product overview1 text field

Centenary Institute is a world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to complex health challenges. The institute conducts research across five primary centers: Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy. Rather than offering commercial software products, the institute focuses on biomedical research, training postdoctoral and postgraduate students, hosting symposia and events, and translating discoveries into clinical applications through its commercialization initiatives.

Product and service6 records
1Biomedical AI Research
CategoryBiomedical Research Services
Description

Research service combining directed evolution of proteins inside mammalian cells with machine learning, enabling therapeutic protein design and regenerative medicine research for collaborating academic and clinical partners.

2Cancer Innovations Research
CategoryCancer Research Services
Description

Translational cancer research service covering melanoma, breast cancer, liver cancer, and AML, including liquid biopsy development, VIRMA targeting, and the Invasion-Block drug screening tool for cancer cell spread.

3Cardiovascular Research
CategoryCardiovascular Research Services
Description

Research service investigating genetic variants in inherited heart diseases, developing stem cell-based therapeutic approaches, and conducting vascular biology and endothelial cell dysfunction research.

4Infection & Immunity Research
CategoryInfectious Disease Research Services
Description

Research service covering tuberculosis vaccine and biomarker development, infectious disease research using PC3 containment, liver immunology, and respiratory disease studies including asthma and COPD.

5Rare Diseases & Gene Therapy Research
CategoryGene Therapy Research Services
Description

Research service developing gene and stem cell therapies, including islet-cell replacement therapies for type 1 diabetes and engineered cell treatments for conditions such as GvHD.

6Vaxosome Multiplex mRNA Vaccine Technology
CategoryVaccine Technology Commercialisation
Description

Spin-out company commercialising proprietary multiplex mRNA vaccine technology that delivers multiple antigen-encoding instructions via lipid nanoparticles in a single vaccine, enabling broader immune protection against pathogens such as tuberculosis.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Vaxosome
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Spin-out company co-founded by Centenary Institute and University of Sydney to develop next-generation multiplex mRNA vaccines targeting tuberculosis and other infectious diseases. Based on foundational research from both institutions. Selected for NSW Government RNA Pipeline Grant.

centenary.org.au
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

$900,000 Translational Fellowship funding and collaborative research framework for cancer research translation between research and clinical settings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Formal affiliation with University of Sydney enabling academic collaboration, student supervision, joint research programs, and technology transfer. Co-founded Vaxosome spin-out company together with Centenary Institute.

4Sydney Local Health District
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Affiliated health district providing clinical research infrastructure and enabling translation of discoveries through Royal Prince Alfred Hospital and other district facilities.

centenary.org.au
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration including joint appointments and translational research partnerships in precision oncology and liquid biopsy development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Clinical collaboration in cancer research including head and neck cancer blood test discovery and metastatic cancer research with shared clinical oversight.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founders of Vaxosome alongside Dr Claudio Counoupas, contributing vaccine development expertise to the multiplex mRNA vaccine program.

8Tuberculosis Centre of Research Excellence (TB-CRE)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Centenary Institute hosted the 2026 TB-CRE Annual Research Symposium. Partnership focuses on TB control across Australia and Asia-Pacific region through collaborative research.

centenary.org.au
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborated on blood test discovery research to identify head and neck cancer patients at higher risk of relapse.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Centenary Institute hosted a World Health Organization Tuberculosis training session, demonstrating international standing in TB research and policy.

11Tianjin Medical University
Strategic tierMajorTypeStrategic or Co-development Partner
Description

International collaboration with researchers from Tianjin Medical University on liver disease research including liver cross-talk and fatty liver disease studies.

centenary.org.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-located hospital providing clinical research infrastructure and enabling direct translation of laboratory discoveries into clinical practice.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

ARC-funded protein design project led by Professor Colin Jackson at ANU, with Associate Professor Daniel Hesselson as Partner Investigator, combining directed evolution and machine learning for therapeutic protein development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

COVID-19 research collaboration within the Centenary UTS Centre for Inflammation, combining institutional capabilities for pandemic response and respiratory disease research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1The Walter and Eliza Hall Institute of Medical Research (WEHI)
TypeDirect peer
Description

Australia's largest medical research institute, working across cancer, immunology and infectious diseases with a similar academic-hospital co-location model, directly comparable in mission and scale of operation to Centenary.

TypeDirect peer
Description

Australia-based independent medical research institute with overlapping programs in cancer genomics, immunology, and translational genomics — Centenary already collaborates with Garvan on precision oncology and liquid biopsy, making it the closest direct peer.

TypeDirect peer
Description

Queensland-based medical research institute with parallel programs in infectious disease, immunology and cancer genetics, and a comparable funding model of grants, philanthropy, and commercialisation.

4Children's Medical Research Institute
TypeDirect peer
Description

Sydney-based independent medical research institute focused on gene therapy and rare diseases, a direct thematic peer to Centenary's Centre for Rare Diseases & Gene Therapy.

TypeEmerging player
Description

UK-based genomics and biomedical research institute whose postdoctoral training alumni (Dr Tiffen) lead Centenary programs — comparable as a model of research-intensive, technology-enabled biomedical institute with commercial spin-out pipelines.

6Peter MacCallum Cancer Centre
TypeBroad incumbent
Description

Australia's largest dedicated cancer hospital and research centre, with deeper oncology focus than Centenary but overlapping expertise in melanoma, breast and pancreatic cancer research and translational pipelines.

TypeDirect peer
Description

Independent Australian medical research institute specialising in cardiovascular and metabolic disease, a direct thematic peer to Centenary's Centre for Cardiovascular Research.

TypeDirect peer
Description

Perth-based medical research institute focused on cancer and chronic diseases with embedded hospital research infrastructure, a similar independent nonprofit research model to Centenary.

TypeDirect peer
Description

University of Melbourne-affiliated institute for infection and immunity, directly comparable in infectious-disease and immunology research areas and in clinical-translation integration.

TypeDirect peer
Description

Independent medical research institute in Adelaide with similar disease-area breadth (cancer, cardiovascular, infectious disease) and university-health district affiliations analogous to Centenary's governance.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Centenary Institute

Medical Researchcentenary.org.au

Centenary Institute is an independent nonprofit medical research institute in Sydney, Australia, conducting translational research across cancer, cardiovascular, infectious, rare, and age-related diseases through five research centres, affiliated with the University of Sydney and Sydney Local Health District.

What Centenary Institute does

Centenary Institute (legally Centenary Institute of Cancer Medicine and Cell Biology) is an independent, nonprofit medical research institute headquartered at Royal Prince Alfred Hospital in Camperdown, Sydney, Australia. Established around 1980, the institute operates across five research centres: Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy. Research spans cancer (melanoma, breast, liver, lung, AML), cardiovascular disease, infectious diseases (particularly tuberculosis and COVID-19), rare diseases, liver disease, diabetes, respiratory diseases, and age-related conditions. The institute is formally affiliated with the University of Sydney and Sydney Local Health District, enabling direct clinical translation through co-location with hospital infrastructure and partnerships with organisations such as Chris O'Brien Lifehouse, Garvan Institute, and NSW Health Pathology.

The institute employs advanced biomedical technologies including a PC3 high-containment facility for live pathogen research, spatial biology platforms developed with the University of Sydney, a multiplex mRNA vaccine platform (commercialised via the Vaxosome spin-out), a mammalian cell protein evolution platform combining directed evolution with machine learning, and the Invasion-Block melanoma screening tool. AI and machine learning are applied within dedicated programmes including protein design and computational biomedicine. Revenue is generated through a diversified mix of competitive government grants (NHMRC, MRFF, ARC, NSW Health, Cancer Australia), philanthropic donations under Deductible Gift Recipient status, industry partnerships with pharmaceutical and biotech firms, financial partnerships with charitable foundations such as Snow Medical Research Foundation ($15.5M) and Breakthrough T1D, and commercialisation/licensing income from spin-out companies. The institute does not sell commercial products and operates on a grant-funded, nonprofit model with no publicly disclosed revenue or ARR figures.

Centenary Institute firmographics

Firmographics
Name
Centenary Institute
Legal name
Centenary Institute of Cancer Medicine and Cell Biology
Website
https://centenary.org.au
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
101–250 employees
Short description
Centenary Institute is an independent nonprofit medical research institute in Sydney, Australia, conducting translational research across cancer, cardiovascular, infectious, rare, and age-related diseases through five research centres, affiliated with the University of Sydney and Sydney Local Health District.
Ownership category
akta.pro rank

Centenary Institute industry classification

Industry
Product category
Medical Research
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYEDAHABAC
Health & Biomedical Research Universities (Academic Medical Center–Affiliated)

Keywords

  • Medical research institute
  • Biomedical research
  • Cancer research
  • Infectious disease research
  • Cardiovascular research

Where Centenary Institute is headquartered

Location

Headquarters

HQ city
Camperdown
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Centenary Institute business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Government Research Grants: Competitive funding from Australian government bodies including NHMRC, MRFF (Medical Research Future Fund), NSW Cardiovascular Research Capacity Program, ARC Discovery Projects, and Cancer Australia. These grants support specific research programs and projects across disease areas.
  2. Donations and Philanthropy: Charitable donations from individuals, supporters, and trusts including workplace giving programs, fundraising events, bequests, and donations in memory. The institute operates with Deductible Gift Recipient (DGR) status enabling tax-deductible donations.
  3. Commercialisation and Licensing: Revenue from spin-out companies and commercial partnerships arising from research discoveries, such as Vaxosome mRNA vaccine technology. May include licensing royalties from patented discoveries.
  4. Industry Partnerships and Grants: Funding from pharmaceutical companies, biotech firms, and charitable foundations including Breakthrough T1D, Tour de Cure, Snow Medical Research Foundation ($15.5M), and others for specific research collaborations.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

Centenary Institute product offering

Product offering

Core offering

Centenary Institute is an independent medical research institute that conducts laboratory and translational research across five research centres (Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy). It translates basic science discoveries into clinical applications through hospital partnerships, commercialises research via spin-out companies (e.g., Vaxosome), and trains postdoctoral and postgraduate students.

Product overview

Centenary Institute is a world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to complex health challenges. The institute conducts research across five primary centers: Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy. Rather than offering commercial software products, the institute focuses on biomedical research, training postdoctoral and postgraduate students, hosting symposia and events, and translating discoveries into clinical applications through its commercialization initiatives.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biomedical AI Research Research service combining directed evolution of proteins inside mammalian cells with machine learning, enabling therapeutic protein design and regenerative medicine research for collaborating academic and clinical partners.
  • Cancer Innovations Research Translational cancer research service covering melanoma, breast cancer, liver cancer, and AML, including liquid biopsy development, VIRMA targeting, and the Invasion-Block drug screening tool for cancer cell spread.
  • Cardiovascular Research Research service investigating genetic variants in inherited heart diseases, developing stem cell-based therapeutic approaches, and conducting vascular biology and endothelial cell dysfunction research.
  • Infection & Immunity Research Research service covering tuberculosis vaccine and biomarker development, infectious disease research using PC3 containment, liver immunology, and respiratory disease studies including asthma and COPD.
  • Rare Diseases & Gene Therapy Research Research service developing gene and stem cell therapies, including islet-cell replacement therapies for type 1 diabetes and engineered cell treatments for conditions such as GvHD.
  • Vaxosome Multiplex mRNA Vaccine Technology Spin-out company commercialising proprietary multiplex mRNA vaccine technology that delivers multiple antigen-encoding instructions via lipid nanoparticles in a single vaccine, enabling broader immune protection against pathogens such as tuberculosis.

Quantifiable outcome

  • TB vaccine candidates developed including fully synthetic TB vaccine and CysVac2 protein fusion vaccine with lung-resident memory T cell promotion.
  • +4 more outcomes

Companies that use Centenary Institute

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Centenary Institute technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Centenary Institute partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered flagship, major and core.

  • VaxosomeflagshipStrategic or Co-development Partner · 10 March 2026Spin-out company co-founded by Centenary Institute and University of Sydney to develop next-generation multiplex mRNA vaccines targeting tuberculosis and other infectious diseases. Based on foundational research from both institutions. Selected for NSW Government RNA Pipeline Grant.
  • Sydney Cancer PartnersmajorStrategic or Co-development Partner · 1 February 2023$900,000 Translational Fellowship funding and collaborative research framework for cancer research translation between research and clinical settings.
  • University of SydneycoreStrategic or Co-development PartnerFormal affiliation with University of Sydney enabling academic collaboration, student supervision, joint research programs, and technology transfer. Co-founded Vaxosome spin-out company together with Centenary Institute.
  • Sydney Local Health DistrictcoreStrategic or Co-development PartnerAffiliated health district providing clinical research infrastructure and enabling translation of discoveries through Royal Prince Alfred Hospital and other district facilities.
  • Garvan Institute of Medical ResearchmajorStrategic or Co-development PartnerResearch collaboration including joint appointments and translational research partnerships in precision oncology and liquid biopsy development.
  • Chris O'Brien LifehousemajorStrategic or Co-development PartnerClinical collaboration in cancer research including head and neck cancer blood test discovery and metastatic cancer research with shared clinical oversight.
  • University of Sydney - Professor Jamie Triccas and Associate Professor Megan SteaincoreStrategic or Co-development PartnerCo-founders of Vaxosome alongside Dr Claudio Counoupas, contributing vaccine development expertise to the multiplex mRNA vaccine program.
  • Tuberculosis Centre of Research Excellence (TB-CRE)majorStrategic or Co-development PartnerCentenary Institute hosted the 2026 TB-CRE Annual Research Symposium. Partnership focuses on TB control across Australia and Asia-Pacific region through collaborative research.
  • NSW Health PathologymajorStrategic or Co-development PartnerCollaborated on blood test discovery research to identify head and neck cancer patients at higher risk of relapse.
  • World Health OrganizationcoreStrategic or Co-development PartnerCentenary Institute hosted a World Health Organization Tuberculosis training session, demonstrating international standing in TB research and policy.
  • Tianjin Medical UniversitymajorStrategic or Co-development PartnerInternational collaboration with researchers from Tianjin Medical University on liver disease research including liver cross-talk and fatty liver disease studies.
  • Royal Prince Alfred HospitalcoreStrategic or Co-development PartnerCo-located hospital providing clinical research infrastructure and enabling direct translation of laboratory discoveries into clinical practice.
  • Australian National UniversitymajorStrategic or Co-development PartnerARC-funded protein design project led by Professor Colin Jackson at ANU, with Associate Professor Daniel Hesselson as Partner Investigator, combining directed evolution and machine learning for therapeutic protein development.
  • University of Technology Sydney (UTS)majorStrategic or Co-development PartnerCOVID-19 research collaboration within the Centenary UTS Centre for Inflammation, combining institutional capabilities for pandemic response and respiratory disease research.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Centenary Institute competitors and assessment

Company assessment

Direct peers

  • The Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's largest medical research institute, working across cancer, immunology and infectious diseases with a similar academic-hospital co-location model, directly comparable in mission and scale of operation to Centenary.
  • Garvan Institute of Medical Research: Australia-based independent medical research institute with overlapping programs in cancer genomics, immunology, and translational genomics — Centenary already collaborates with Garvan on precision oncology and liquid biopsy, making it the closest direct peer.
  • QIMR Berghofer Medical Research Institute: Queensland-based medical research institute with parallel programs in infectious disease, immunology and cancer genetics, and a comparable funding model of grants, philanthropy, and commercialisation.
  • Children's Medical Research Institute: Sydney-based independent medical research institute focused on gene therapy and rare diseases, a direct thematic peer to Centenary's Centre for Rare Diseases & Gene Therapy.
  • Baker Heart and Diabetes Institute: Independent Australian medical research institute specialising in cardiovascular and metabolic disease, a direct thematic peer to Centenary's Centre for Cardiovascular Research.
  • Harry Perkins Institute of Medical Research: Perth-based medical research institute focused on cancer and chronic diseases with embedded hospital research infrastructure, a similar independent nonprofit research model to Centenary.
  • Doherty Institute: University of Melbourne-affiliated institute for infection and immunity, directly comparable in infectious-disease and immunology research areas and in clinical-translation integration.
  • South Australian Health and Medical Research Institute (SAHMRI): Independent medical research institute in Adelaide with similar disease-area breadth (cancer, cardiovascular, infectious disease) and university-health district affiliations analogous to Centenary's governance.

Emerging players

  • Wellcome Sanger Institute: UK-based genomics and biomedical research institute whose postdoctoral training alumni (Dr Tiffen) lead Centenary programs — comparable as a model of research-intensive, technology-enabled biomedical institute with commercial spin-out pipelines.

Broad incumbents

  • Peter MacCallum Cancer Centre: Australia's largest dedicated cancer hospital and research centre, with deeper oncology focus than Centenary but overlapping expertise in melanoma, breast and pancreatic cancer research and translational pipelines.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Centenary Institute social profiles

Digital presence

Centenary Institute financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Centenary Institute leadership team

Management profile

Number of profiles

Profiles8 records

Centenary Institute funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Centenary Institute M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centenary Institute

What does Centenary Institute do?

Centenary Institute is an independent medical research institute that conducts laboratory and translational research across five research centres (Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy). It translates basic science discoveries into clinical applications through hospital partnerships, commercialises research via spin-out companies (e.g., Vaxosome), and trains postdoctoral and postgraduate students.

Is Centenary Institute a public or private company?

Centenary Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Centenary Institute founded?

Centenary Institute was founded in 1980. It employs 101 to 250 people.

Where is Centenary Institute based?

Centenary Institute is headquartered in Camperdown, Australia, in the Oceania region.

How does Centenary Institute make money?

Four revenue lines are on record. Government Research Grants are the primary driver. The others are donations and Philanthropy, commercialisation and Licensing and industry Partnerships and Grants.

Who are Centenary Institute's main competitors?

Direct peers on record are The Walter and Eliza Hall Institute of Medical Research (WEHI), Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, Children's Medical Research Institute, Baker Heart and Diabetes Institute, Harry Perkins Institute of Medical Research, Doherty Institute and South Australian Health and Medical Research Institute (SAHMRI). Wellcome Sanger Institute is listed as an emerging player. Peter MacCallum Cancer Centre is listed as a broad incumbent.

Does Centenary Institute have an API?

No public API is recorded for Centenary Institute.

What industry is Centenary Institute in?

Centenary Institute's product category is Medical Research. Its primary akta.pro industry code is EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based), with a secondary code of EDAHABAC, Health & Biomedical Research Universities (Academic Medical Center–Affiliated). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNew Laboratories Strengthen Centenary Institute ResearchThe Centenary Institute established four new research laboratories in infection and immunity, respiratory disease, and biomedical AI. The labs focus on tuberculosis, influenza, COPD, and melanoma, and the institute now has 17 such laboratories.Mirage NewsNew Laboratories Strengthen Centenary Institute ResearchThe Centenary Institute established four new research laboratories in infection and immunity, respiratory disease, and biomedical AI. The labs, led by researchers including Professor Colin Jackson and Dr Yagiz Aksoy, focus on diseases such as tuberculosis, influenza, COPD, and melanoma. The institute now has 17 world-class medical research laboratories.MedicalxpressModified BCG vaccine strengthens protection against TBResearchers from the Centenary Institute and University of Sydney developed a modified BCG vaccine that targets dendritic cells, improving immune response and protection against TB in mice. The modified vaccine showed stronger and longer-lasting protection than standard BCG in preclinical tests. The team is now optimizing the vaccine for further investigation.Mirage NewsModified BCG Vaccine Strengthens Protection Against TBResearchers from the Centenary Institute and University of Sydney developed a modified BCG vaccine that showed stronger and more sustained protection against TB in preclinical mouse tests. The modification targeted dendritic cells, improving immune response and lung protection lasting longer than standard BCG.News-MedicalInfluenza research could pave way for new and improved drugs, vaccinesResearchers at the Centenary Institute and University of Sydney found that a lung cell type responds poorly to interferons during influenza infection, making it highly vulnerable. The study, published in Cell Reports, could lead to new anti-influenza drugs and vaccines. The team plans to study human lung cells next.News-MedicalNew type of vaccine targets deadly tuberculosisAustralian researchers from the Centenary Institute and University of Sydney developed a new tuberculosis vaccine that protected mice from experimental airborne TB infection. The vaccine uses two peptides bound to an adjuvant to stimulate protective T cells in the lungs. The team plans to test whether it can be adapted for human use.News-MedicalStudy finds new way to target escalating rates of obesityResearchers at the Centenary Institute and UNSW developed a drug targeting Ceramide Synthase enzymes, published in Nature Communications. The drug reduced lipid accumulation in skeletal muscle but did not prevent insulin resistance in mice, instead increasing fat burning. Future drugs targeting both Ceramide Synthase 1 and 6 enzymes are planned.ABCEnergy drinks could be deadly for young people with heart conditions, study findsA joint study from the University of Sydney, RPA, and the Centenary Institute found energy drinks increase sudden cardiac death risk in young people with Long QT Syndrome, a condition affecting one in 2,000. Participants showed over 10% blood pressure rise, and the Beverage Council called the results limiting due to small sample size.